Generic Name and Formulations:
Pentoxifylline 400mg; ext-rel tabs.
Various generic manufacturers
Indications for Pentoxifylline:
400mg three times daily with meals. Continue for at least 8 weeks. Digestive or CNS effects: lower dosage to 400mg twice daily; discontinue if side effects persist. Severe renal impairment (CrCl <30mL/min): 400mg once daily.
Recent cerebral or retinal hemorrhage. Methylxanthines intolerance (eg, caffeine, theophylline, theobromine).
Discontinue if anaphylactic/anaphylactoid reaction occurs. Monitor for bleeding including hematocrit, hemoglobin in patients with hemorrhagic risk factors (eg, recent surgery, peptic ulcer, cerebral and/or retinal bleeding). Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hemorrheologic agent (xanthine).
See Contraindications. May potentiate antihypertensives; monitor BP. Concomitant theophylline-containing drugs; monitor closely and adjust dose. Bleeding with concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. Concomitant warfarin; monitor PT frequently. May be potentiated by strong CYP1A2 inhibitors (eg, ciprofloxacin, fluvoxamine), cimetidine.
GI upset, nausea, dyspepsia, flushing, agitation, headache, dizziness, insomnia, blurred vision.
Formerly known under the brand name Trental.
Renal (primarily), fecal.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC